MNG1231
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.398
- KRAS_SIGNALING_DN+0.353
- SPERMATOGENESIS+0.140
- MYOGENESIS+0.091
- APICAL_SURFACE+0.021
- KRAS_SIGNALING_UP-0.057
- COAGULATION-0.062
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.097
- APICAL_JUNCTION-0.098
- ESTROGEN_RESPONSE_LATE-0.104
Top 10 suppressed
- MYC_TARGETS_V1-0.571
- UNFOLDED_PROTEIN_RESPONSE-0.517
- INTERFERON_ALPHA_RESPONSE-0.512
- PROTEIN_SECRETION-0.500
- MTORC1_SIGNALING-0.476
- DNA_REPAIR-0.471
- E2F_TARGETS-0.465
- INTERFERON_GAMMA_RESPONSE-0.456
- OXIDATIVE_PHOSPHORYLATION-0.448
- G2M_CHECKPOINT-0.445
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR650204 | — | — | 0.975 |
| 2 | c7d31245-5d71-4a23-8a33-4f83c4718e20 | — | — | 0.971 |
| 3 | 08e3d239-3d8a-4eee-9e08-ac2bcb3f2619 | — | — | 0.969 |
| 4 | MNG598 | — | — | 0.967 |
| 5 | msclc569389_S35.txt | — | cohortMD1 | 0.965 |
| 6 | MNG560 | — | — | 0.965 |
| 7 | 8ad884fa-e426-4bc0-960d-08db42d341da | — | — | 0.964 |
| 8 | MNG226 | — | — | 0.964 |
| 9 | MNG1259 | — | — | 0.963 |
| 10 | MNG597 | — | — | 0.961 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 5 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.398 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.353 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| MYOGENESIS | 0.091 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.021 | Temsirolimus | — uncovered |